Call customer care on: 0333 358 0200

9 Reasons You’re Not Getting the Best Results on GLP-1 Medications

With the Evidence

GLP-1 receptor agonists, such as semaglutide (Wegovy or Ozempic) and tirzepatide (Mounjaro), are proven treatments for weight management and type 2 diabetes in the UK when prescribed appropriately. In routine care, titration, follow-up, and what to do after a missed dose should follow the UK product and patient information for your medicine, alongside what you agree with your prescriber, not informal dosing advice from social media. The same active ingredients may be marketed under different names in other countries (for example Zepbound for weight-loss tirzepatide in the United States). Some people still see slower or smaller changes than expected. Below are nine evidence-based reasons why results may vary, grounded in clinical guidance and the research cited at the end of the article.

1. Not Reaching the Maintenance Dose

GLP-1 injections usually start low and step up to limit nausea and other side effects. Staying below a maintenance-equivalent dose for too long, or delaying agreed increases, often caps how much change you will see on scans or the scales.
In the trials: The largest weight-loss results came from participants who reached and stayed on full maintenance doses.1,2

2. Irregular or Missed Doses

Skipping injections or drifting from your agreed day-of-the-week pattern makes drug levels swing; you may feel hungrier again or lose glycaemic benefit between doses.
What the PIL underlines: These medicines are designed around steady once-weekly use; the UK patient information for your product sets out how to handle missed doses.3

3. Not Eating Enough Protein

When total calories fall but protein stays low, a larger share of weight lost can be lean tissue, not fat.
Evidence: Higher protein during caloric restriction better preserves lean mass in weight-loss studies.4

4. Drinking Too Many Liquid Calories

Alcohol, juices, smoothies, and sweet coffees add energy fast yet rarely trigger the same fullness as solid meals.
Mechanism: Liquid calories are handled differently from solid food in appetite research, so drinks can blunt progress even when injections are working.5

5. Eating High-Calorie, Low-Volume Foods

Chocolate, pastries, fried takeaways, and similar foods pack a lot of calories into a small portion, so it is easy to out-eat the deficit your medication helps create.
Energy density: Human feeding studies show people tend to eat more calories overall when meals are more calorie-dense, independent of appetite hormones alone.6

6. Not Focusing on Strength Training

Aerobic activity alone, without loaded movement, often means more lean loss for a given amount of scale weight change.
Guidelines: UK obesity management guidance and international diabetes standards both stress preserving muscle and function during weight loss, not chasing the scale at any cost.7,8

7. Stress and Poor Sleep

Short sleep and persistent stress shift hunger hormones and food choice in ways that look “like weak willpower” on the outside.
Research: Experimental sleep restriction raises ghrelin and self-reported appetite; separate work links chronic stress to ad libitum intake.9,10

8. Expecting Results Too Quickly

Week four is not week fifty-two: semaglutide and tirzepatide trials kept measuring out past a year because responders often continued to drift down slowly while on study drug.
Trajectory: Both STEP and SURMOUNT programmes reported sustained change over many months on maintenance-intensity dosing, not a single early plateau for everyone.1,11

9. Underlying Medical Conditions or Other Medications

Untreated hypothyroidism, marked insulin resistance, PCOS-related androgen patterns, and perimenopausal hormone swings can all blunt how quickly fat mass falls. Glucocorticoids, several antidepressants, and some antipsychotics are among the drugs that commonly move weight or glycaemia independently of your GLP-1 dose.
Clinical context: NICE pathways for obesity and type 2 diabetes assume comorbidities and other medicines are reviewed, not ignored, when weight stalls.2,12

Summary

Used as intended, GLP-1-based treatment in the UK is among the most effective pharmacological options for obesity and related glycaemic problems, but it is not a passive implant: dose, adherence, sleep, stress, food choice, and muscle loading all still matter. The payoff is usually better when your prescriber can adjust the plan as real life gets in the way, rather than leaving you guessing after a plateau.

References

  1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
  2. NICE Technology Appraisal TA875: Semaglutide, 2023.
  3. Electronic Medicines Compendium (UK). Wegovy (semaglutide): patient information leaflet.
  4. Leidy HJ, et al. Higher protein intake preserves lean mass during weight loss. American Journal of Clinical Nutrition, 2015.
  5. DiMeglio DP, Mattes RD. Liquid calories and reduced appetite suppression. American Journal of Clinical Nutrition, 2000.
  6. Rolls BJ. High‑energy‑density foods increase calorie intake. Annual Review of Nutrition, 2009.
  7. NICE Guideline NG246: Overweight and obesity management (UK).
  8. American Diabetes Association. Standards of Care in Diabetes, 2024.
  9. Spiegel K, et al. Sleep restriction reduces leptin, increases ghrelin, and increases appetite. Annals of Internal Medicine, 2004.
  10. Jackson SE, et al. Stress increases calorie intake independent of hunger. Obesity Journal, 2017.
  11. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  12. NICE Guideline NG28: Type 2 diabetes in adults: management, 2023.

How it works

Get personalised care
02. Get personalised care

We'll provide you with a tailored treatment plan from a UK registered doctor

Get next day delivery
03. Get next day delivery

Receive genuine medication shipped discreetly to your door

Did you know?

Over 40% of the population has tried to lose weight at some point in the last 5 years – so you're certainly not alone

Chat on WhatsApp